Kidney Health and Renal Resilience Protocol
Nutri-Stasis Protocol Series
Kidney Health &
Renal Resilience
Renal Resilience
Reduce Risk · Support Function · Protect the Long Game
A research-grounded supplementation and lifestyle protocol designed to support kidney function, reduce modifiable risk factors associated with renal decline, and promote long-term renal resilience.
35.5M
U.S. adults with CKD
1 in 7
American adults affected
9 in 10
Unaware they have it
34%
Prevalence over age 65
Who This Protocol Is For
This is a supportive protocol for adults who want to be proactive about kidney health — especially those with metabolic, blood pressure, cardiovascular, or aging-related risk factors. It is not a treatment for chronic kidney disease and does not replace nephrology care, medications, or laboratory follow-up. Individuals with diagnosed CKD Stage 3b or above, dialysis, or significant medication complexity should review supplement changes with a physician.
The Stack
Four Compounds. Four Mechanisms.
Every compound in this stack targets a distinct but overlapping mechanism in kidney health: glomerular inflammation, mitochondrial oxidative stress, nutrient deficiency, and vascular calcification. All four are supported by peer-reviewed RCTs or meta-analyses in human CKD populations.
| Supplement | Dose | Timing | Primary Role |
|---|---|---|---|
| Omega-3 EPA/DHA | 2,000–4,000mg/day | With meals | Reduce glomerular inflammation, lower proteinuria, support slower eGFR decline |
| CoQ10 (Ubiquinone) | 600–1,200mg/day | With fat-containing meal | Mitochondrial support, reduce oxidative stress, repletes CKD-depleted CoQ10 |
| Vitamin D3 2,000 IU | 2,000–5,000 IU/day | With largest meal | Correct near-universal deficiency, regulate PTH, vascular and immune support |
| Magnesium Glycinate | 300–400mg elemental/day | Evening | Inhibit vascular calcification, BP regulation, repletes CKD-depleted magnesium |
Add Full Stack to Cart — Save 10%
Discount code PROTOCOL10 applied automatically at checkout.
The Research
What the Indexed Literature Supports
Every compound in this protocol is supported by at least one randomized controlled trial, systematic review, or meta-analysis in human CKD populations. Animal and mechanistic data are noted where relevant but are not used as primary justification.
| Compound | Study Type | Key Finding | Evidence |
|---|---|---|---|
| Omega-3 EPA/DHA | Pooled analysis — 19 cohorts (BMJ 2023) & 9-RCT meta-analysis | Lower CKD incidence, slower eGFR decline, reduced proteinuria | Strong |
| CoQ10 | CKD-specific RCTs (AJKD 2016; JCI Insight 2024) | Significantly reduced oxidative stress biomarkers; improved mitochondrial bioenergetics in moderate-to-severe CKD | Moderate |
| Vitamin D3 | Systematic review / meta-analysis (AJKD 2023) | Improves vascular function and reduces PTH; direct eGFR effects less consistent | Moderate |
| Magnesium | Focused review (Clin Exp Nephrol 2022) | Low magnesium associated with vascular calcification, cardiovascular mortality, and CKD progression | Moderate |
Emerging Research — Not in Current Stack
Astragalus membranaceus
A 2024 multi-center RCT (Chan et al., Phytomedicine) found that add-on oral astragalus further stabilized kidney function versus standard care alone in 118 patients with type-2 diabetic CKD over 48 weeks. The proposed mechanisms include reduced NF-kB signaling, lower IL-6 and TNF-alpha activity, TGF-beta/Smad inhibition, and podocyte protection. Astragalus is not currently available through our fulfillment partner and is therefore not included in the purchasable stack. It is included here as the most compelling botanical candidate under active sourcing evaluation.
Daily Schedule
Protocol at a Glance
| Time | Action | Why |
|---|---|---|
| Morning with breakfast | Omega-3 2,000–4,000mg · CoQ10 600–1,200mg · Vitamin D3 2,000–5,000 IU | Fat-soluble compounds require food for absorption. AM dosing is practical and consistent. |
| Evening with dinner or before bed | Magnesium Glycinate 300–400mg elemental | Evening dosing supports sleep quality and GI tolerance. |
| Optional | Split omega-3 dose AM / PM if using 4,000mg and GI sensitivity is an issue | Improves tolerance and may sustain steadier EPA/DHA plasma levels. |
What to Track
Annual comprehensive metabolic panel — eGFR, creatinine, BUN, electrolytes, and urine albumin-to-creatinine ratio (UACR)
25-hydroxyvitamin D [25(OH)D] annually — target 40–60 ng/mL; adjust D3 dose to results
Serum magnesium if available — target 0.85–1.10 mmol/L
Blood pressure — home monitoring at least twice per week
Fasting glucose and HbA1c if at metabolic risk
Omega-3 index (EPA+DHA % of red blood cell fatty acids) — target above 8% for optimal anti-inflammatory effect
Lifestyle Foundations
The Non-Negotiable Pillars
No supplement protocol overrides foundational behavior. The largest modifiable reductions in CKD progression come from lifestyle. These pillars are the prerequisite, not the afterthought.
Blood glucose management — Keep fasting glucose and HbA1c in range. Hyperglycemia is the single largest driver of kidney damage in diabetic CKD.
Blood pressure control — Target below 130/80 mmHg. Sodium restriction, hydration, movement, and medication adherence all matter.
Protein calibration — High protein intake increases glomerular filtration pressure in existing CKD. Review target intake with a nephrologist if CKD is diagnosed.
Hydration — Adequate fluid intake unless advanced CKD or heart failure requires restriction. Target 2–3 liters daily.
Aerobic exercise — 150 min/week of moderate-intensity exercise independently improves eGFR, blood pressure, and cardiovascular risk in CKD populations.
NSAID avoidance — Chronic NSAID use is nephrotoxic. Avoid ibuprofen and naproxen unless directed by a physician.
Safety & Contraindications
Consult a Physician First If…
Physician Consultation Required
You have been diagnosed with CKD Stage 3b or above (eGFR <45)
You are on dialysis or have been advised dialysis is imminent
You take blood thinners (warfarin, apixaban, rivaroxaban) — omega-3 has a mild anticoagulant effect
You take prescribed medications for blood pressure or diabetes
You have a history of hypercalcemia or hyperphosphatemia
You take statins — CoQ10 may interact with statin metabolism
You are pregnant or nursing
The Magnesium Paradox in CKD
Magnesium deficiency is common in early-to-moderate CKD (Stages 1–3b) because tubular dysfunction impairs reabsorption. However, in advanced CKD (Stages 4–5), the kidneys may no longer excrete excess magnesium efficiently. Supplementation is most appropriate for Stages 1–3b. Do not supplement magnesium without physician approval if eGFR is below 30 mL/min/1.73m².
CoQ10 Dosing Note
The Nutri-Stasis CoQ10 (Ubiquinone) product is formulated at 200mg per capsule — appropriate for general antioxidant support. The therapeutic doses used in the CKD-specific clinical trials (600–1,200mg/day) require 3–6 capsules daily. Discuss the appropriate dose with your physician or nephrologist before scaling to trial-level dosing.
Download the Full Protocol Guide
16-page research document — full mechanisms, clinical evidence, dosing rationale, daily schedule, safety profiles, and 16 indexed references.
Educational use only. Not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before beginning any supplementation program.